C4 Therapeutics Inc. (CCCC)
4.15
+0.23 (5.87%)
Upcoming Events
Latest Headlines
Form 8-K C4 Therapeutics, Inc. For: Jun 11
June 11, 2026 7:05 AM - SEC Filing
C4 Therapeutics reports 53% response rate in myeloma drug trial
June 11, 2026 7:00 AM - StreetInsider
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pret
June 11, 2026 7:00 AM - StreetInsider
Form 4 C4 Therapeutics, Inc. For: Jun 01 Filed by: Anderson Kenneth Carl
June 4, 2026 4:15 PM - SEC Filing
Form 144 C4 Therapeutics, Inc. Filed by: Mossler Mark
May 28, 2026 8:32 PM - SEC Filing
C4 Therapeutics to Participate in Upcoming Conferences
May 20, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G C4 Therapeutics, Inc. Filed by: Squadron Capital Management LLC
May 19, 2026 4:10 PM - SEC Filing
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026 4:01 PM - Globe NewsWire
Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:29 PM - SEC Filing
Form 8-K C4 Therapeutics, Inc. For: May 15
May 15, 2026 4:05 PM - SEC Filing
Form SCHEDULE 13G C4 Therapeutics, Inc. Filed by: Sirenia Capital Management LP
May 15, 2026 8:11 AM - SEC Filing
C4 Therapeutics, Inc. (CCCC) Tops Q1 EPS by 5c
May 12, 2026 7:20 AM - StreetInsider
Form 10-Q C4 Therapeutics, Inc. For: Mar 31
May 12, 2026 7:08 AM - SEC Filing
Form 8-K C4 Therapeutics, Inc. For: May 12
May 12, 2026 7:06 AM - SEC Filing
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026 7:01 AM - Globe NewsWire
Form ARS C4 Therapeutics, Inc. For: Apr 29
April 29, 2026 7:05 AM - SEC Filing
Form DEFA14A C4 Therapeutics, Inc.
April 29, 2026 7:03 AM - SEC Filing
Form DEF 14A C4 Therapeutics, Inc. For: Apr 29
April 29, 2026 7:01 AM - SEC Filing
Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: WASATCH ADVISORS LP
April 22, 2026 5:28 PM - SEC Filing
Form 8-K C4 Therapeutics, Inc. For: Apr 10
April 10, 2026 7:17 AM - SEC Filing
Form 8-K C4 Therapeutics, Inc. For: Apr 09
April 9, 2026 7:08 AM - SEC Filing
C4 Therapeutics expands Roche partnership with new DAC collaboration
April 9, 2026 6:59 AM - StreetInsider
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
April 9, 2026 6:59 AM - Globe NewsWire
Form 4 C4 Therapeutics, Inc. For: Apr 01 Filed by: Anderson Kenneth Carl
April 3, 2026 10:46 AM - SEC Filing
Form 4 C4 Therapeutics, Inc. For: Apr 01 Filed by: GROGAN DONNA ROY
April 3, 2026 10:46 AM - SEC Filing
C4 Therapeutics begins Phase 1b trial of cemsidomide with elranatamab
March 25, 2026 7:00 AM - StreetInsider
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
March 25, 2026 7:00 AM - StreetInsider
Full Article List
